National Cancer Institute NCI Cancer Bulletin: A Trusted Source for Cancer Research News
October 18, 2011 • Volume 8 / Number 20

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
AHRQ Update

Public Comment Sought on Draft Prostate Cancer Screening Recommendation

The U.S. Preventive Services Task Force (USPSTF) last week issued a draft recommendation against using the prostate-specific antigen (PSA) test to screen healthy men for prostate cancer if they do not have symptoms “that are highly suspicious for prostate cancer.”

The draft recommendation was based on a review of findings from clinical trials of prostate cancer screening and clinical trials and cohort studies of treatment for prostate cancers diagnosed primarily on the basis of PSA screening. The recommendation does not cover PSA testing as part of “a diagnostic strategy in men with symptoms that are highly suspicious for prostate cancer,” the Task Force wrote, or “the use of the PSA test for surveillance after diagnosis and/or treatment of prostate cancer.”

A public comment period on the draft recommendation is open until November 8. Comments should address the draft recommendation “and how the [USPSTF] decisions are communicated,” the Task Force explained.

Comments may be submitted via the USPSTF website or via mail to Dr. Robert Cosby,
c/o USPSTF, 540 Gaither Road, Rockville, MD 20850. 

Public Comment Sought on Updated Cervical Cancer Screening Recommendations

On October 18, the U.S. Preventive Services Task Force (USPSTF) issued draft recommendations on screening for cervical cancer. The recommendations are an update of previous task force recommendations and are open for a 30-day public comment period. 

The draft recommendations advise that screening with the Pap test should be done every 3 years for women ages 21 to 65 who have had vaginal intercourse and have a cervix. In women younger than age 30, the recommendations advise against screening using human papillomavirus (HPV) testing, either alone or in combination with the Pap test. In women 30 years of age and older, the task force concluded, “the current evidence is insufficient to assess the balance of benefits and harms of HPV testing, alone or in combination with [a Pap test].” 

The public comment period on the draft recommendation is open until November 16. Comments may be submitted via the USPSTF website or via mail to Dr. Robert Cosby, c/o USPSTF, 540 Gaither Road, Rockville, MD 20850.

< Previous Section  |  Next Section >